4-Hydroxybutyric Acid
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Gamma Hydroxybutyric Acid.
Abiraterone
The serum concentration of Prochlorperazine can be increased when it is combined with Abiraterone.
Acebutolol
Prochlorperazine may increase the hypotensive activities of Acebutolol.
Advertisement
Acepromazine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Acepromazine.
Aceprometazine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Aceprometazine.
Acetyl Sulfisoxazole
The metabolism of Prochlorperazine can be decreased when combined with Acetyl sulfisoxazole.
Advertisement
Alfaxalone
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Alfaxalone.
Alfentanil
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Alfentanil.
Almotriptan
The risk or severity of adverse effects can be increased when Almotriptan is combined with Prochlorperazine.
Advertisement
Aloglutamol
Aloglutamol can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Alphaprodine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Alphaprodine.
Alprazolam
The risk or severity of adverse effects can be increased when Alprazolam is combined with Prochlorperazine.
Alprenolol
Prochlorperazine may increase the hypotensive activities of Alprenolol.
Aluminum
Aluminium can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aluminum Hydroxide
Aluminum hydroxide can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
aluminum hydroxide, dried (USP)
Aluminum hydroxide can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aluminum Magnesium Silicate
Almasilate can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Amantadine
The therapeutic efficacy of Prochlorperazine can be decreased when used in combination with Amantadine.
Amiodarone
The metabolism of Prochlorperazine can be decreased when combined with Amiodarone.
Amisulpride
Prochlorperazine may increase the antipsychotic activities of Amisulpride.
Amitriptyline
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Amitriptyline.
Amobarbital
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Amobarbital.
Amodiaquine
The serum concentration of Prochlorperazine can be increased when it is combined with Amodiaquine.
Amoxapine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Amoxapine.
Amphetamine
Prochlorperazine may decrease the stimulatory activities of Amphetamine.
Apalutamide
The serum concentration of Prochlorperazine can be decreased when it is combined with Apalutamide.
Apomorphine
The therapeutic efficacy of Prochlorperazine can be decreased when used in combination with Apomorphine.
Aprepitant
The serum concentration of Prochlorperazine can be increased when it is combined with Aprepitant.
Aripiprazole
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Aripiprazole.
Artemether
The serum concentration of Prochlorperazine can be increased when it is combined with Artemether.
Artesunate
The serum concentration of Prochlorperazine can be increased when it is combined with Artesunate.
Articaine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Articaine.
Asenapine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Asenapine.
Atazanavir
The metabolism of Prochlorperazine can be decreased when combined with Atazanavir.
Atenolol
Prochlorperazine may increase the hypotensive activities of Atenolol.
Atomoxetine
The metabolism of Prochlorperazine can be decreased when combined with Atomoxetine.
Atovaquone
The serum concentration of Prochlorperazine can be increased when it is combined with Atovaquone.
Azelastine
Prochlorperazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Baclofen
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Baclofen.
Barbital
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Barbital.
Benoxinate
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Oxybuprocaine.
Benperidol
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Benperidol.
Benzocaine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Benzocaine.
Benzphetamine
Prochlorperazine may decrease the stimulatory activities of Benzphetamine.
Benzyl Alcohol
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Benzyl alcohol.
Benzylpenicilloyl polylysine
Prochlorperazine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.
BETAHISTINE
The therapeutic efficacy of Betahistine can be decreased when used in combination with Prochlorperazine.
Betaxolol
The metabolism of Prochlorperazine can be decreased when combined with Betaxolol.
Bismuth Subcitrate
Bismuth Subcitrate can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Bismuth Subnitrate
Bismuth subnitrate can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Bisoprolol
Prochlorperazine may increase the hypotensive activities of Bisoprolol.
Boceprevir
The metabolism of Prochlorperazine can be decreased when combined with Boceprevir.
Bopindolol
Prochlorperazine may increase the hypotensive activities of Bopindolol.
Bortezomib
The metabolism of Prochlorperazine can be decreased when combined with Bortezomib.
Bosentan
The serum concentration of Prochlorperazine can be decreased when it is combined with Bosentan.
Bosentan Anhydrous
The serum concentration of Prochlorperazine can be decreased when it is combined with Bosentan.
Brexpiprazole
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Brexpiprazole.
Brimonidine
Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.
Bromazepam
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Bromazepam.
Bromocriptine
The therapeutic efficacy of Prochlorperazine can be decreased when used in combination with Bromocriptine.
Bromperidol
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Bromperidol.
Brompheniramine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Brompheniramine.
Brotizolam
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Brotizolam.
Bupivacaine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Bupivacaine.
Bupranolol
Prochlorperazine may increase the hypotensive activities of Bupranolol.
Buprenorphine
Prochlorperazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Bupropion
The metabolism of Prochlorperazine can be decreased when combined with Bupropion.
Buspirone
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Buspirone.
Butabarbital
The risk or severity of adverse effects can be increased when Butabarbital is combined with Prochlorperazine.
Butalbital
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Butalbital.
Butamben
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Butamben.
Butobarbital
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Butethal.
Butorphanol
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Butorphanol.
Cabergoline
The risk or severity of adverse effects can be increased when Cabergoline is combined with Prochlorperazine.
Calcium Carbonate
Calcium Carbonate can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
CALCIUM CARBONATE, PRECIPITATED
Calcium Carbonate can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Carbamazepine
The metabolism of Prochlorperazine can be increased when combined with Carbamazepine.
Carbinoxamine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Carbinoxamine.
Carisoprodol
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Carisoprodol.
Carteolol
Prochlorperazine may increase the hypotensive activities of Carteolol.
Carvedilol
Prochlorperazine may increase the hypotensive activities of Carvedilol.
Celecoxib
The metabolism of Prochlorperazine can be decreased when combined with Celecoxib.
Celiprolol
Prochlorperazine may increase the hypotensive activities of Celiprolol.
Ceritinib
The serum concentration of Prochlorperazine can be increased when it is combined with Ceritinib.
Cetirizine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Cetirizine.
Chloral Hydrate
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Chloral hydrate.
Chlordiazepoxide
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Chlordiazepoxide.
Chlormethiazole
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with clomethiazole.
Chlormezanone
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Chlormezanone.
Chloroprocaine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Chloroprocaine.
Chloroquine
The serum concentration of Prochlorperazine can be increased when it is combined with Chloroquine.
Chlorpheniramine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Chlorphenamine.
CHLORPHENIRAMINE POLISTIREX
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Chlorphenamine.
Chlorpromazine
The metabolism of Prochlorperazine can be decreased when combined with Chlorpromazine.
Chlorprothixene
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Chlorprothixene.
Chlorzoxazone
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Chlorzoxazone.
Cholecalciferol
The metabolism of Prochlorperazine can be decreased when combined with Cholecalciferol.
Cimetidine
The metabolism of Prochlorperazine can be decreased when combined with Cimetidine.
Cinacalcet
The metabolism of Prochlorperazine can be decreased when combined with Cinacalcet.
Citalopram
The metabolism of Prochlorperazine can be decreased when combined with Citalopram.
Clarithromycin
The metabolism of Prochlorperazine can be decreased when combined with Clarithromycin.
Clemastine
The metabolism of Prochlorperazine can be decreased when combined with Clemastine.
Clidinium
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Clidinium.
Clidinium bromide
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Clidinium.
Clobazam
The metabolism of Prochlorperazine can be decreased when combined with Clobazam.
Clomipramine
The metabolism of Prochlorperazine can be decreased when combined with Clomipramine.
Clonazepam
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Clonazepam.
Clonidine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Clonidine.
Clorazepate
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Clorazepate.
CLORAZEPIC ACID
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Clorazepate.
Clotrimazole
The metabolism of Prochlorperazine can be decreased when combined with Clotrimazole.
Clozapine
The metabolism of Prochlorperazine can be decreased when combined with Clozapine.
Cobicistat
The serum concentration of Prochlorperazine can be increased when it is combined with Cobicistat.
Cocaine
The metabolism of Prochlorperazine can be decreased when combined with Cocaine.
Codeine
The risk or severity of adverse effects can be increased when Codeine is combined with Prochlorperazine.
Codeine Anhydrous
The risk or severity of adverse effects can be increased when Codeine is combined with Prochlorperazine.
CODEINE POLISTIREX
The risk or severity of adverse effects can be increased when Codeine is combined with Prochlorperazine.
Conivaptan
The serum concentration of Conivaptan can be increased when it is combined with Prochlorperazine.
Crizotinib
The metabolism of Prochlorperazine can be decreased when combined with Crizotinib.
Curcumin
The metabolism of Prochlorperazine can be decreased when combined with Curcumin.
Cyclizine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Cyclizine.
Cyclobenzaprine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Cyclobenzaprine.
Cyclosporine
The metabolism of Prochlorperazine can be decreased when combined with Cyclosporine.
Cyproheptadine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Cyproheptadine.
Dabrafenib
The serum concentration of Prochlorperazine can be decreased when it is combined with Dabrafenib.
Dantrolene
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dantrolene.
Dapiprazole
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dapiprazole.
Dapsone
The serum concentration of Prochlorperazine can be increased when it is combined with Dapsone.
Darifenacin
The metabolism of Prochlorperazine can be decreased when combined with Darifenacin.
Darunavir
The serum concentration of Prochlorperazine can be increased when it is combined with Darunavir.
Dasatinib
The serum concentration of Prochlorperazine can be increased when it is combined with Dasatinib.
Dasatinib Anhydrous
The serum concentration of Prochlorperazine can be increased when it is combined with Dasatinib.
Deferasirox
The serum concentration of Prochlorperazine can be decreased when it is combined with Deferasirox.
Deferoxamine
The risk or severity of adverse effects can be increased when Deferoxamine is combined with Prochlorperazine.
Delavirdine
The metabolism of Prochlorperazine can be decreased when combined with Delavirdine.
Desflurane
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Desflurane.
Desipramine
The metabolism of Prochlorperazine can be decreased when combined with Desipramine.
Desloratadine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Desloratadine.
Desvenlafaxine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Desvenlafaxine.
Deutetrabenazine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Deutetrabenazine.
Dexbrompheniramine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dexbrompheniramine.
Dexmedetomidine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dexmedetomidine.
Dextroamphetamine
Prochlorperazine may decrease the stimulatory activities of Dextroamphetamine.
Dextromethorphan
The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Prochlorperazine.
Dextromoramide
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dextromoramide.
Dezocine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dezocine.
Diazepam
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Diazepam.
Dibucaine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Cinchocaine.
Diethylpropion
Prochlorperazine may decrease the stimulatory activities of Diethylpropion.
Difenoxin
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Difenoxin.
Dihydrocodeine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dihydrocodeine.
Dihydroergotamine
The metabolism of Prochlorperazine can be decreased when combined with Dihydroergotamine.
Diltiazem
The metabolism of Prochlorperazine can be decreased when combined with Diltiazem.
Dimenhydrinate
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dimenhydrinate.
Diphenhydramine
The metabolism of Prochlorperazine can be decreased when combined with Diphenhydramine.
Diphenoxylate
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Diphenoxylate.
Dofetilide
The serum concentration of Dofetilide can be increased when it is combined with Prochlorperazine.
Dothiepin
The metabolism of Prochlorperazine can be decreased when combined with Dosulepin.
Doxepin
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Doxepin.
Doxycycline
The serum concentration of Prochlorperazine can be increased when it is combined with Doxycycline.
Doxycycline Anhydrous
The serum concentration of Prochlorperazine can be increased when it is combined with Doxycycline.
Doxylamine
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.
Dronedarone
The metabolism of Prochlorperazine can be decreased when combined with Dronedarone.
Droperidol
Droperidol may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.
Duloxetine
The metabolism of Prochlorperazine can be decreased when combined with Duloxetine.
Dyclonine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dyclonine.
Efavirenz
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Efavirenz.
Eletriptan
The risk or severity of adverse effects can be increased when Eletriptan is combined with Prochlorperazine.
Eliglustat
The metabolism of Prochlorperazine can be decreased when combined with Eliglustat.
Enflurane
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Enflurane.
Entacapone
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Entacapone.
Enzalutamide
The serum concentration of Prochlorperazine can be decreased when it is combined with Enzalutamide.
ergoloid mesylates, USP
The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Prochlorperazine.
Ergonovine
The risk or severity of adverse effects can be increased when Ergonovine is combined with Prochlorperazine.
Ergotamine
The risk or severity of adverse effects can be increased when Ergotamine is combined with Prochlorperazine.
Erythromycin
The metabolism of Prochlorperazine can be decreased when combined with Erythromycin.
Escitalopram
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Escitalopram.
Esmolol
Prochlorperazine may increase the hypotensive activities of Esmolol.
Estazolam
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Estazolam.
Eszopiclone
The risk or severity of adverse effects can be increased when Eszopiclone is combined with Prochlorperazine.
Ethanol
Prochlorperazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Ethchlorvynol
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ethchlorvynol.
Ethosuximide
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ethosuximide.
Ethotoin
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ethotoin.
Ethyl Chloride
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ethyl chloride.
Ethyl Loflazepate
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ethyl loflazepate.
Ethylmorphine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ethylmorphine.
Etidocaine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Etidocaine.
Etifoxine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Etifoxine.
Etomidate
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Etomidate.
Ezogabine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ezogabine.
Felbamate
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Felbamate.
Fenfluramine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Fenfluramine.
Fentanyl
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Fentanyl.
Fexofenadine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Fexofenadine.
Flibanserin
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Flibanserin.
Fluconazole
The metabolism of Prochlorperazine can be decreased when combined with Fluconazole.
Flunarizine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Flunarizine.
Flunitrazepam
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Flunitrazepam.
Fluoxetine
The metabolism of Prochlorperazine can be decreased when combined with Fluoxetine.
Flupenthixol
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Flupentixol.
Fluphenazine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Fluphenazine.
Flurazepam
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Flurazepam.
Fluspirilene
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Fluspirilene.
Fluticasone propionate
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Fluticasone propionate.
Fluvoxamine
The metabolism of Prochlorperazine can be decreased when combined with Fluvoxamine.
Fosamprenavir
The metabolism of Prochlorperazine can be decreased when combined with Fosamprenavir.
Fosaprepitant
The serum concentration of Prochlorperazine can be increased when it is combined with Fosaprepitant.
Fosphenytoin
The metabolism of Prochlorperazine can be increased when combined with Fosphenytoin.
Fospropofol
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Fospropofol.
Frovatriptan
The risk or severity of adverse effects can be increased when Frovatriptan is combined with Prochlorperazine.
Fusidate
The serum concentration of Prochlorperazine can be increased when it is combined with Fusidic Acid.
Fusidic Acid
The serum concentration of Prochlorperazine can be increased when it is combined with Fusidic Acid.
Gabapentin
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Gabapentin.
Gabapentin Enacarbil
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Gabapentin Enacarbil.
Glutethimide
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Glutethimide.
Guanfacine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Guanfacine.
Halazepam
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Halazepam.
Halofantrine
The serum concentration of Prochlorperazine can be increased when it is combined with Halofantrine.
Haloperidol
The metabolism of Prochlorperazine can be decreased when combined with Haloperidol.
Halothane
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Halothane.
Heroin
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Heroin.
Hexobarbital
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Hexobarbital.
Hyaluronidase
The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Prochlorperazine.
Hyaluronidase, Ovine
The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Prochlorperazine.
Hydrocodone
Prochlorperazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
HYDROCODONE POLISTIREX
Prochlorperazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydromorphone
The risk or severity of adverse effects can be increased when Hydromorphone is combined with Prochlorperazine.
Hydrotalcite
Hydrotalcite can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Hydroxychloroquine
The serum concentration of Prochlorperazine can be increased when it is combined with Hydroxychloroquine.
Hydroxyzine
Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.
Hypoxis hemerocallidea root extract
The serum concentration of Prochlorperazine can be decreased when it is combined with St. John's Wort.
Idelalisib
The metabolism of Prochlorperazine can be decreased when combined with Idelalisib.
Iloperidone
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Iloperidone.
Imatinib
The metabolism of Prochlorperazine can be decreased when combined with Imatinib.
Imipramine
The metabolism of Prochlorperazine can be decreased when combined with Imipramine.
Indinavir
The metabolism of Prochlorperazine can be decreased when combined with Indinavir.
INDINAVIR ANHYDROUS
The metabolism of Prochlorperazine can be decreased when combined with Indinavir.
Isavuconazole
The serum concentration of Prochlorperazine can be increased when it is combined with Isavuconazole.
Isavuconazonium
The metabolism of Prochlorperazine can be decreased when combined with Isavuconazonium.
Isocarboxazid
The therapeutic efficacy of Prochlorperazine can be increased when used in combination with Isocarboxazid.
Isoflurane
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Isoflurane.
Isoniazid
The metabolism of Prochlorperazine can be decreased when combined with Isoniazid.
Isradipine
The metabolism of Prochlorperazine can be decreased when combined with Isradipine.
Itraconazole
The metabolism of Prochlorperazine can be decreased when combined with Itraconazole.
Ivacaftor
The serum concentration of Prochlorperazine can be increased when it is combined with Ivacaftor.
Ketamine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ketamine.
Ketazolam
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ketazolam.
Ketoconazole
The metabolism of Prochlorperazine can be decreased when combined with Ketoconazole.
Labetalol
Prochlorperazine may increase the hypotensive activities of Labetalol.
Lamotrigine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Lamotrigine.
Levetiracetam
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Levetiracetam.
Levobetaxolol
Prochlorperazine may increase the hypotensive activities of Levobetaxolol.
Levobunolol
Prochlorperazine may increase the hypotensive activities of Levobunolol.
Levobupivacaine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Levobupivacaine.
Levocabastine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Levocabastine.
Levocetirizine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Levocetirizine.
Levodopa
The therapeutic efficacy of Prochlorperazine can be decreased when used in combination with Levodopa.
Levomethadyl
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Levomethadyl Acetate.
Levomilnacipran
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Levomilnacipran.
Levorphanol
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Levorphanol.
Lidocaine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Lidocaine.
Linezolid
The risk or severity of adverse effects can be increased when Linezolid is combined with Prochlorperazine.
Lisdexamfetamine
Prochlorperazine may decrease the stimulatory activities of Lisdexamfetamine.
Lisdexamfetamine Dimesylate
Prochlorperazine may decrease the stimulatory activities of Lisdexamfetamine.
Lithium
Lithium may increase the neurotoxic activities of Prochlorperazine.
Lithium Cation
Lithium may increase the neurotoxic activities of Prochlorperazine.
Lofexidine
The therapeutic efficacy of Prochlorperazine can be increased when used in combination with Lofexidine.
Lopinavir
The metabolism of Prochlorperazine can be decreased when combined with Lopinavir.
Loratadine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Loratadine.
Lorazepam
The risk or severity of adverse effects can be increased when Lorazepam is combined with Prochlorperazine.
Lorcaserin
The metabolism of Prochlorperazine can be decreased when combined with Lorcaserin.
Lormetazepam
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Lormetazepam.
Lovastatin
The metabolism of Prochlorperazine can be decreased when combined with Lovastatin.
Loxapine
The risk or severity of adverse effects can be increased when Loxapine is combined with Prochlorperazine.
Luliconazole
The serum concentration of Prochlorperazine can be increased when it is combined with Luliconazole.
Lumacaftor
The metabolism of Prochlorperazine can be increased when combined with Lumacaftor.
Lumefantrine
The serum concentration of Prochlorperazine can be increased when it is combined with Lumefantrine.
Lurasidone
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Lurasidone.
Magaldrate
Magaldrate can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium Carbonate
Magnesium carbonate can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium Hydroxide
Magnesium hydroxide can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium Oxide
Magnesium oxide can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium silicate
Magnesium silicate can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium Sulfate
The therapeutic efficacy of Prochlorperazine can be increased when used in combination with Magnesium sulfate.
MAGNESIUM SULFATE ANHYDROUS
The therapeutic efficacy of Prochlorperazine can be increased when used in combination with Magnesium sulfate.
Magnesium Trisilicate
Magnesium Trisilicate can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Manidipine
The metabolism of Prochlorperazine can be decreased when combined with Manidipine.
Maprotiline
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Maprotiline.
Meclizine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Meclizine.
Mefloquine
The serum concentration of Prochlorperazine can be increased when it is combined with Mefloquine.
Melatonin
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Melatonin.
Meperidine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Pethidine.
Mephentermine
Prochlorperazine may decrease the stimulatory activities of Mephentermine.
Mephobarbital
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methylphenobarbital.
Mepindolol
Prochlorperazine may increase the hypotensive activities of Mepindolol.
Mepivacaine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Mepivacaine.
Meprobamate
The risk or severity of adverse effects can be increased when Meprobamate is combined with Prochlorperazine.
Mequitazine
Prochlorperazine may increase the arrhythmogenic activities of Mequitazine.
Mesoridazine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Mesoridazine.
Metaxalone
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Metaxalone.
Methadone
The metabolism of Prochlorperazine can be decreased when combined with Methadone.
Methadyl Acetate
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methadyl Acetate.
Methamphetamine
Prochlorperazine may decrease the stimulatory activities of Methamphetamine.
Methapyrilene
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methapyrilene.
Methaqualone
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methaqualone.
Methocarbamol
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methocarbamol.
Methohexital
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methohexital.
Methotrimeprazine
Prochlorperazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Methoxyflurane
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methoxyflurane.
Methsuximide
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methsuximide.
Methylphenidate
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methylphenidate.
Metipranolol
Prochlorperazine may increase the hypotensive activities of Metipranolol.
Metoclopramide
The risk or severity of adverse effects can be increased when Metoclopramide is combined with Prochlorperazine.
Metoprolol
The metabolism of Prochlorperazine can be decreased when combined with Metoprolol.
Metylperon
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Melperone.
Metyrosine
Prochlorperazine may increase the sedative activities of Metyrosine.
Midazolam
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Midazolam.
Midostaurin
The metabolism of Prochlorperazine can be decreased when combined with Midostaurin.
Mifepristone
The serum concentration of Prochlorperazine can be increased when it is combined with Mifepristone.
Milnacipran
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Milnacipran.
Minocycline
Minocycline may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.
Mirabegron
The metabolism of Prochlorperazine can be decreased when combined with Mirabegron.
Mirtazapine
Prochlorperazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Mitotane
The serum concentration of Prochlorperazine can be decreased when it is combined with Mitotane.
Moclobemide
The risk or severity of adverse effects can be increased when Moclobemide is combined with Prochlorperazine.
Molindone
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Molindone.
Morphine
The risk or severity of adverse effects can be increased when Morphine is combined with Prochlorperazine.
Nabilone
Nabilone may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.
Nadolol
Prochlorperazine may increase the hypotensive activities of Nadolol.
Nalbuphine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Nalbuphine.
Naratriptan
The risk or severity of adverse effects can be increased when Naratriptan is combined with Prochlorperazine.
Nebivolol
Prochlorperazine may increase the hypotensive activities of Nebivolol.
Nefazodone
The metabolism of Prochlorperazine can be decreased when combined with Nefazodone.
Nelfinavir
The metabolism of Prochlorperazine can be decreased when combined with Nelfinavir.
Netupitant
The serum concentration of Prochlorperazine can be increased when it is combined with Netupitant.
Nevirapine
The metabolism of Prochlorperazine can be increased when combined with Nevirapine.
Nicardipine
The metabolism of Prochlorperazine can be decreased when combined with Nicardipine.
Nilotinib
The metabolism of Prochlorperazine can be decreased when combined with Nilotinib.
Nitrazepam
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Nitrazepam.
Nitrous Oxide
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Nitrous oxide.
Nordazepam
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Nordazepam.
Norflurane
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Norflurane.
Normethadone
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Normethadone.
Nortriptyline
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Nortriptyline.
Olanzapine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Olanzapine.
Olaparib
The metabolism of Prochlorperazine can be decreased when combined with Olaparib.
Olopatadine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Olopatadine.
Ondansetron
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ondansetron.
Opium
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Opium.
Orphenadrine
Prochlorperazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Osimertinib
The serum concentration of Prochlorperazine can be increased when it is combined with Osimertinib.
Oxazepam
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Oxazepam.
Oxprenolol
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Oxprenolol.
Oxycodone
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Oxycodone.
Oxymorphone
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Oxymorphone.
p-Hydroxyamphetamine
Prochlorperazine may decrease the stimulatory activities of Hydroxyamphetamine.
Palbociclib
The serum concentration of Prochlorperazine can be increased when it is combined with Palbociclib.
Paliperidone
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Paliperidone.
Panobinostat
The serum concentration of Prochlorperazine can be increased when it is combined with Panobinostat.
Paraldehyde
Prochlorperazine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Paregoric
The risk or severity of adverse effects can be increased when Morphine is combined with Prochlorperazine.
Paroxetine
The metabolism of Prochlorperazine can be decreased when combined with Paroxetine.
Peginterferon Alfa-2b
The serum concentration of Prochlorperazine can be decreased when it is combined with Peginterferon alfa-2b.
Penbutolol
Prochlorperazine may increase the hypotensive activities of Penbutolol.
Pentazocine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Pentazocine.
Pentobarbital
The metabolism of Prochlorperazine can be increased when combined with Pentobarbital.
Perampanel
Perampanel may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.
Perazine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Perazine.
Perphenazine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Perphenazine.
Phenelzine
The risk or severity of adverse effects can be increased when Phenelzine is combined with Prochlorperazine.
Phenobarbital
The metabolism of Prochlorperazine can be increased when combined with Phenobarbital.
Phenoxyethanol
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Phenoxyethanol.
Phentermine
Prochlorperazine may decrease the stimulatory activities of Phentermine.
PHENTERMINE RESIN
Prochlorperazine may decrease the stimulatory activities of Phentermine.
Phenytoin
The metabolism of Prochlorperazine can be increased when combined with Phenytoin.
Pimozide
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Pimozide.
Pindolol
Prochlorperazine may increase the hypotensive activities of Pindolol.
Pipamperone
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Pipamperone.
Pipothiazine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Pipotiazine.
Piribedil
The therapeutic efficacy of Prochlorperazine can be decreased when used in combination with Piribedil.
Pirinitramide
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Piritramide.
Pizotyline
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Pizotifen.
Pomalidomide
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Pomalidomide.
Posaconazole
The metabolism of Prochlorperazine can be decreased when combined with Posaconazole.
Practolol
Prochlorperazine may increase the hypotensive activities of Practolol.
Pramipexole
Prochlorperazine may increase the sedative activities of Pramipexole.
Pramoxine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Pramocaine.
Prazepam
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Prazepam.
Pregabalin
The therapeutic efficacy of Prochlorperazine can be increased when used in combination with Pregabalin.
Prilocaine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Prilocaine.
Primaquine
The serum concentration of Prochlorperazine can be increased when it is combined with Primaquine.
Primidone
The metabolism of Prochlorperazine can be increased when combined with Primidone.
Procaine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Procaine.
Procarbazine
The risk or severity of adverse effects can be increased when Procarbazine is combined with Prochlorperazine.
Proguanil
The serum concentration of Prochlorperazine can be increased when it is combined with Proguanil.
Promazine
The metabolism of Prochlorperazine can be decreased when combined with Promazine.
Promethazine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Promethazine.
Propafenone
Prochlorperazine may increase the hypotensive activities of Propafenone.
Proparacaine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Proparacaine.
Propofol
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Propofol.
Propoxyphene
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dextropropoxyphene.
Propranolol
Prochlorperazine may increase the hypotensive activities of Propranolol.
Protriptyline
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Protriptyline.
Pseudoephedrine
Prochlorperazine may decrease the stimulatory activities of Pseudoephedrine.
Pyrimethamine
The serum concentration of Prochlorperazine can be increased when it is combined with Pyrimethamine.
Quazepam
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Quazepam.
Quetiapine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Quetiapine.
Quetiapine fumarate
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Quetiapine.
Quinacrine
The serum concentration of Prochlorperazine can be increased when it is combined with Quinacrine.
Quinagolide
The therapeutic efficacy of Quinagolide can be decreased when used in combination with Prochlorperazine.
Quinidine
The metabolism of Prochlorperazine can be decreased when combined with Quinidine.
Quinine
The serum concentration of Prochlorperazine can be increased when it is combined with Quinine.
Ramelteon
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ramelteon.
Ranolazine
The metabolism of Prochlorperazine can be decreased when combined with Ranolazine.
Rasagiline
The risk or severity of adverse effects can be increased when Rasagiline is combined with Prochlorperazine.
Remifentanil
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Remifentanil.
Remoxipride
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Remoxipride.
Reserpine
The risk or severity of adverse effects can be increased when Reserpine is combined with Prochlorperazine.
Rifabutin
The metabolism of Prochlorperazine can be increased when combined with Rifabutin.
Rifampin
The metabolism of Prochlorperazine can be increased when combined with Rifampicin.
Rifapentine
The metabolism of Prochlorperazine can be increased when combined with Rifapentine.
Risperidone
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Risperidone.
Ritonavir
The metabolism of Prochlorperazine can be decreased when combined with Ritonavir.
Rizatriptan
The risk or severity of adverse effects can be increased when Rizatriptan is combined with Prochlorperazine.
Rolapitant
The metabolism of Prochlorperazine can be decreased when combined with Rolapitant.
Ropinirole
Prochlorperazine may increase the sedative activities of Ropinirole.
Ropivacaine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ropivacaine.
Rotigotine
Prochlorperazine may increase the sedative activities of Rotigotine.
Rucaparib
The metabolism of Prochlorperazine can be decreased when combined with Rucaparib.
Rufinamide
The risk or severity of adverse effects can be increased when Rufinamide is combined with Prochlorperazine.
Saquinavir
The metabolism of Prochlorperazine can be decreased when combined with Saquinavir.
Saquinavir Mesylate
The metabolism of Prochlorperazine can be decreased when combined with Saquinavir.
Sarilumab
The therapeutic efficacy of Prochlorperazine can be decreased when used in combination with Sarilumab.
Scopolamine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Scopolamine.
Scopolamine Hydrobromide
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Scopolamine.
Secobarbital
The risk or severity of adverse effects can be increased when Secobarbital is combined with Prochlorperazine.
Selegiline
The risk or severity of adverse effects can be increased when Selegiline is combined with Prochlorperazine.
Sertindole
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Sertindole.
Sertraline
The metabolism of Prochlorperazine can be decreased when combined with Sertraline.
Sevoflurane
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Sevoflurane.
Sildenafil
The metabolism of Prochlorperazine can be decreased when combined with Sildenafil.
Siltuximab
The serum concentration of Prochlorperazine can be decreased when it is combined with Siltuximab.
Simeprevir
The serum concentration of Prochlorperazine can be increased when it is combined with Simeprevir.
Sodium Bicarbonate
Sodium bicarbonate can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Sodium Oxybate
Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.
Sotalol
Prochlorperazine may increase the hypotensive activities of Sotalol.
ST. JOHN'S WORT EXTRACT
The serum concentration of Prochlorperazine can be decreased when it is combined with St. John's Wort.
Sufentanil
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Sufentanil.
Sulfadoxine
The serum concentration of Prochlorperazine can be increased when it is combined with Sulfadoxine.
Sulfalene
The serum concentration of Prochlorperazine can be increased when it is combined with Sulfametopyrazine.
Sulfisoxazole
The metabolism of Prochlorperazine can be decreased when combined with Sulfisoxazole.
Sulpiride
Prochlorperazine may increase the antipsychotic activities of Sulpiride.
Sumatriptan
The risk or severity of adverse effects can be increased when Sumatriptan is combined with Prochlorperazine.
Sumatriptan Succinate
The risk or severity of adverse effects can be increased when Sumatriptan is combined with Prochlorperazine.
Suvorexant
Prochlorperazine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Talinolol
Prochlorperazine may increase the hypotensive activities of Talinolol.
Tapentadol
Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.
Tasimelteon
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Tasimelteon.
Tedizolid
The risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Prochlorperazine.
Tedizolid Phosphate
The risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Prochlorperazine.
Telaprevir
The metabolism of Prochlorperazine can be decreased when combined with Telaprevir.
Telithromycin
The metabolism of Prochlorperazine can be decreased when combined with Telithromycin.
Temazepam
The risk or severity of adverse effects can be increased when Temazepam is combined with Prochlorperazine.
Terbinafine
The metabolism of Prochlorperazine can be decreased when combined with Terbinafine.
Terbutaline
Prochlorperazine may increase the hypotensive activities of Terbutaline.
Terbutaline Sulfate
Prochlorperazine may increase the hypotensive activities of Terbutaline.
Tertatolol
Prochlorperazine may increase the hypotensive activities of Tertatolol.
Tetrabenazine
The risk or severity of adverse effects can be increased when Tetrabenazine is combined with Prochlorperazine.
Tetracaine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Tetracaine.
Tetracaine hydrochloride
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Tetracaine.
Tetrahydrocannabinol
Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.
Thalidomide
Prochlorperazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Thiamylal
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Thiamylal.
Thiopental
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Thiopental.
Thiopental Sodium
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Thiopental.
Thioridazine
The metabolism of Prochlorperazine can be decreased when combined with Thioridazine.
Thiothixene
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Thiothixene.
Tiagabine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Tiagabine.
Tiapride
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Tiapride.
Ticlopidine
The metabolism of Prochlorperazine can be decreased when combined with Ticlopidine.
Timolol
Prochlorperazine may increase the hypotensive activities of Timolol.
Timolol Anhydrous
Prochlorperazine may increase the hypotensive activities of Timolol.
Tipranavir
The metabolism of Prochlorperazine can be decreased when combined with Tipranavir.
Tizanidine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Tizanidine.
Tocilizumab
The serum concentration of Prochlorperazine can be decreased when it is combined with Tocilizumab.
Tolcapone
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Tolcapone.
Topiramate
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Topiramate.
Tramadol
The risk or severity of adverse effects can be increased when Tramadol is combined with Prochlorperazine.
Tranylcypromine
The metabolism of Prochlorperazine can be decreased when combined with Tranylcypromine.
Trazodone
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Trazodone.
Triazolam
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Triazolam.
Triazulenone
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Loprazolam.
Trifluoperazine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Trifluoperazine.
Triflupromazine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Triflupromazine.
Trimethoprim
The serum concentration of Prochlorperazine can be increased when it is combined with Trimethoprim.
Trimipramine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Trimipramine.
Triprolidine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Triprolidine.
Tromethamine
Tromethamine can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Urethane
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ethyl carbamate.
Valproate
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Valproic Acid.
Valproic Acid
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Valproic Acid.
Vemurafenib
The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Prochlorperazine.
Venlafaxine
The metabolism of Prochlorperazine can be decreased when combined with Venlafaxine.
Verapamil
The metabolism of Prochlorperazine can be decreased when combined with Verapamil.
Vigabatrin
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Vigabatrin.
Vilazodone
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Vilazodone.
Voriconazole
The metabolism of Prochlorperazine can be decreased when combined with Voriconazole.
Vortioxetine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Vortioxetine.
Xylazine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Xylazine.
Zaleplon
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Zaleplon.
Ziconotide
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ziconotide.
Ziprasidone
The metabolism of Prochlorperazine can be decreased when combined with Ziprasidone.
Zolmitriptan
The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Prochlorperazine.
Zolpidem
Prochlorperazine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Zonisamide
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Zonisamide.
Zopiclone
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Zopiclone.
Zotepine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Zotepine.
Zuclopenthixol
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Zuclopenthixol.
